Immunomedics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Immunomedics Inc (IMMU) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Immunomedics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 2M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-28.2% annualized vs trailing 12 months).
- Peer revenue share: Immunomedics Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
IMMU Sales vs. its Competitors, Q2 2018
Immunomedics Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the In Vitro & In Vivo Diagnostic Substances industry grew revenue 2.5% year over year, combined, vs -39.7% for Immunomedics Inc. Immunomedics Inc's share of combined industry revenue moved from 0.02% to 0.01%, a loss of 0.01 percentage points.
Immunomedics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Immunomedics Inc | - | - | - | No |
| High-Confidence Competitors (3) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
IMMU Stock Performance relative to its Competitors
IMMU Stock Performance relative to High-Confidence Competitors
Immunomedics Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Sutro Biopharma Inc | Named by the company | 85% |
| Immutep Limited | Named by the company | 85% |
| Vincerx Pharma Inc | Named by the company | 85% |
| Oncosec Medical Incorporated | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Immunomedics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.